Not because it's easier, but because we believe consistency is built through verification, documentation, and accountability
What if my dose is 2.5 mg but my vial is 5 mg/mL
The current evidence base points to several overlapping molecular pathways operating in parallel: VEGFR2/Akt/eNOS Angiogenic Signalling A primary mechanistic axis involves upregulation of vascular endothelial growth factor receptor 2 (VEGFR2), leading to activation of the Akt/eNOS (endothelial nitric oxide synthase) downstream pathway
Inhibition of Glucagon Release GLP-1 helps regulate blood sugar by inhibiting glucagon, a hormone that triggers the liver to release stored glucose, which can raise blood sugar levels
This system operates in different cell compartments and genes, encoding its components are differentially regulated according to the current needs
This activation leads to the upregulation of various cytoprotective and antioxidant proteins